Effective growth hormone replacement with once‐weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial
Work
Year: 2024
Type: article
Abstract: Objective Somapacitan is a long‐acting growth hormone (GH) derivative developed for the treatment of GH deficiency (GHD). This study evaluates the efficacy and tolerability of somapacitan in Japanese... more
Source: Clinical Endocrinology
Institutions Osaka City General Hospital, Osaka University, Hamamatsu University School of Medicine, Novo Nordisk (Switzerland), Novo Nordisk (Denmark) +1 more
Cites: 32
Cited by: 5
Related to: 10
FWCI: 7.029
Citation percentile (by year/subfield): 99.99
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: hybrid
APC paid (est): $4,330
Funder Novo Nordisk